The latest issue of Boston KPro News is available. The new issue features:
- FDA Approval Obtained for the Boston Keratoprosthesis Type I Lucia Design
- Integrating a Pressure Sensor in the Boston KPro
- Boston KPro Usage Chart
- Finding an Optimal Substitute for Human Donor Corneas
- King Khaled Eye Specialist Hospital Keratoprosthesis Center of Excellence
- Pilot Program in Sudan
- Profiles of Distinguished Boston KPro Surgeons
Boston Keratoprosthesis (KPro) is a small, not-for-profit entity within Massachusetts Eye and Ear, a nonprofit specialty hospital and affiliate of Harvard Medical School. Boston KPro markets devices intended for patients with otherwise irreversible corneal blindness in whom repeat corneal transplantation has failed, or because of ocular comorbidities would otherwise be expected to fail. Since the U.S. Food and Drug Administration (FDA) approved the device for marketing in 1992, more than 14,000 Boston KPro devices have been implanted. For patients with bilateral blindness with normal retinal function in at least one eye, but blind due to corneal opacity, implantation of a Boston KPro can lead to a miraculous improvement in vision, the restored capacity to work and study, and the ability to see loved ones’ faces and to appreciate all the visual wonders the rest of us with normal vision take for granted.